CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Catalyst Pharmaceuticals - CPRX CFD

    14.10
    1.12%
    0.09
    Low: 14.1
    High: 14.35
    Market Trading Hours* (UTC) Opens on Monday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Catalyst Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 14.26
    Open* 14.12
    1-Year Change* -15.65%
    Day's Range* 14.1 - 14.35
    52 wk Range 11.09-22.11
    Average Volume (10 days) 1.25M
    Average Volume (3 months) 26.16M
    Market Cap 1.46B
    P/E Ratio 26.15
    Shares Outstanding 106.61M
    Revenue 348.39M
    EPS 0.53
    Dividend (Yield %) N/A
    Beta 1.09
    Next Earnings Date Mar 13, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 7, 2023 14.26 0.32 2.30% 13.94 14.28 13.81
    Dec 6, 2023 13.97 -0.20 -1.41% 14.17 14.35 13.83
    Dec 5, 2023 14.20 -0.46 -3.14% 14.66 14.80 14.05
    Dec 4, 2023 15.01 0.42 2.88% 14.59 15.03 14.59
    Dec 1, 2023 14.78 0.51 3.57% 14.27 14.80 14.27
    Nov 30, 2023 14.42 0.39 2.78% 14.03 14.47 14.01
    Nov 29, 2023 14.00 -0.14 -0.99% 14.14 14.40 13.98
    Nov 28, 2023 14.17 0.20 1.43% 13.97 14.23 13.89
    Nov 27, 2023 14.04 0.11 0.79% 13.93 14.12 13.72
    Nov 24, 2023 14.03 0.20 1.45% 13.83 14.04 13.71
    Nov 22, 2023 13.81 0.06 0.44% 13.75 13.94 13.65
    Nov 21, 2023 13.70 0.13 0.96% 13.57 13.90 13.56
    Nov 20, 2023 13.68 -0.10 -0.73% 13.78 13.86 13.49
    Nov 17, 2023 13.78 0.42 3.14% 13.36 13.83 13.35
    Nov 16, 2023 13.35 -0.27 -1.98% 13.62 13.66 13.21
    Nov 15, 2023 13.61 0.36 2.72% 13.25 13.97 13.20
    Nov 14, 2023 13.34 0.52 4.06% 12.82 13.42 12.82
    Nov 13, 2023 12.59 -0.11 -0.87% 12.70 12.84 12.39
    Nov 10, 2023 12.80 0.35 2.81% 12.45 12.97 12.44
    Nov 9, 2023 12.28 -1.09 -8.15% 13.37 13.37 12.22

    Catalyst Pharmaceuticals Events

    Time (UTC) Country Event
    Wednesday, March 13, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Catalyst Pharmaceuticals Inc Earnings Release
    Q4 2023 Catalyst Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 214.203 140.833 119.073 102.306 0.5
    Revenue 214.203 140.833 119.073 102.306 0.5
    Total Operating Expense 112.365 88.448 77.7696 70.4831 35.7952
    Selling/General/Admin. Expenses, Total 58.183 49.628 44.2337 36.8812 15.876
    Research & Development 19.789 16.936 16.4967 18.8428 19.9192
    Operating Income 101.838 52.385 41.3032 31.8233 -35.2952
    Interest Income (Expense), Net Non-Operating 0
    Other, Net 2.881 0.282 0.5869 1.58577 1.29165
    Net Income Before Taxes 104.719 52.667 41.8901 33.409 -34.0035
    Net Income After Taxes 83.079 39.482 74.983 31.8753 -34.0035
    Net Income Before Extra. Items 83.079 39.482 74.983 31.8753 -34.0035
    Net Income 83.079 39.482 74.983 31.8753 -34.0035
    Income Available to Common Excl. Extra. Items 83.079 39.482 74.983 31.8753 -34.0035
    Income Available to Common Incl. Extra. Items 83.079 39.482 74.983 31.8753 -34.0035
    Diluted Net Income 83.079 39.482 74.983 31.8753 -34.0035
    Diluted Weighted Average Shares 111.376 107.796 106.242 106.021 102.634
    Diluted EPS Excluding Extraordinary Items 0.74594 0.36627 0.70577 0.30065 -0.33131
    Diluted Normalized EPS 0.74594 0.36627 0.70577 0.30065 -0.33131
    Total Extraordinary Items
    Cost of Revenue, Total 34.393 21.884 17.0392 14.7591
    Gross Profit 179.81 118.949 102.034 87.5472
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 99.582 85.366 60.757 57.244 53.113
    Revenue 99.582 85.366 60.757 57.244 53.113
    Cost of Revenue, Total 12.045 9.946 11.195 9.665 7.643
    Gross Profit 87.537 75.42 49.562 47.579 45.47
    Total Operating Expense 52.883 49.757 29.956 32.142 24.544
    Selling/General/Admin. Expenses, Total 28.396 29.718 14.668 14.167 12.918
    Research & Development 3.954 3.562 4.093 8.31 3.983
    Operating Income 46.699 35.609 30.801 25.102 28.569
    Other, Net 1.813 1.704 2.207 0.905 -0.324
    Net Income Before Taxes 48.512 37.313 33.008 26.007 28.245
    Net Income After Taxes 37.762 29.568 25.471 22.748 21.619
    Net Income Before Extra. Items 37.762 29.568 25.471 22.748 21.619
    Net Income 37.762 29.568 25.471 22.748 21.619
    Income Available to Common Excl. Extra. Items 37.762 29.568 25.471 22.748 21.619
    Income Available to Common Incl. Extra. Items 37.762 29.568 25.471 22.748 21.619
    Diluted Net Income 37.762 29.568 25.471 22.748 21.619
    Diluted Weighted Average Shares 113.674 113.986 114.446 111.986 109.265
    Diluted EPS Excluding Extraordinary Items 0.3322 0.2594 0.22256 0.20313 0.19786
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 0.3322 0.2594 0.22256 0.20313 0.19786
    Depreciation / Amortization 8.488 6.531
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 320.797 210.106 159.244 111.364 55.1874
    Cash and Short Term Investments 298.395 191.266 140.278 94.5188 53.4816
    Cash & Equivalents 298.395 171.445 130.237 89.5117 16.5594
    Short Term Investments 0 19.821 10.0411 5.00705 36.9222
    Prepaid Expenses 4.581 4.024 7.79916 3.83441 1.37761
    Other Current Assets, Total 0.577 0.327 0.52862 0.51667 0.27217
    Total Assets 375.63 237.788 192.354 112.376 60.45
    Property/Plant/Equipment, Total - Net 3.617 3.976 0.1298 1.00372 0.24543
    Property/Plant/Equipment, Total - Gross 4.023 4.251 0.44257
    Accumulated Depreciation, Total -0.406 -0.275 -0.19715
    Other Long Term Assets, Total 18.745 23.706 32.9801 0.00889 0.00889
    Total Current Liabilities 57.588 27.063 22.7563 24.0987 9.51135
    Accounts Payable 3.975 2.768 4.25602 4.11745 2.33737
    Accrued Expenses 31.546 23.973 18.0832 16.7403 7.07414
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 22.067 0.322 0.41703 3.24103 0.09984
    Total Liabilities 75.209 30.957 22.7563 24.7463 9.66615
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 17.621 3.894 0 0.64753 0.1548
    Total Equity 300.421 206.831 169.598 87.63 50.7838
    Common Stock 0.105 0.103 0.10378 0.1034 0.10274
    Additional Paid-In Capital 250.43 233.186 223.168 216.206 211.265
    Retained Earnings (Accumulated Deficit) 49.862 -26.31 -53.7056 -128.689 -160.564
    Total Liabilities & Shareholders’ Equity 375.63 237.788 192.354 112.376 60.45
    Total Common Shares Outstanding 105.263 102.993 103.782 103.397 102.739
    Redeemable Preferred Stock 0 0 0 0 0
    Total Inventory 6.805 7.87 4.6506 1.95679 0.05601
    Long Term Investments 0 5.00824
    Other Equity, Total 0.024 -0.148 0.03133 0.00951 -0.02025
    Total Receivables, Net 10.439 6.619 5.98743 10.537
    Accounts Receivable - Trade, Net 10.439 6.619 5.98743 10.537
    Intangibles, Net 32.471
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 192.017 240.968 198.911 320.797 276.31
    Cash and Short Term Investments 120.971 178.787 148.247 298.395 256.065
    Cash & Equivalents 120.971 178.787 148.247 298.395 256.065
    Short Term Investments 0 0
    Total Receivables, Net 48.049 42.796 33.402 10.439 9.337
    Accounts Receivable - Trade, Net 48.049 42.796 33.402 10.439 9.337
    Total Inventory 9.035 10.751 10.328 6.805 7.132
    Prepaid Expenses 13.756 8.452 6.599 4.581 3.31
    Other Current Assets, Total 0.206 0.182 0.335 0.577 0.466
    Total Assets 413.211 443.896 407.227 375.63 333.114
    Property/Plant/Equipment, Total - Net 3.761 3.844 3.991 3.617 3.715
    Property/Plant/Equipment, Total - Gross 4.4 4.401 4.466 4.023 4.087
    Accumulated Depreciation, Total -0.639 -0.557 -0.475 -0.406 -0.372
    Other Long Term Assets, Total 37.428 23.489 20.242 18.745 20.038
    Total Current Liabilities 57.806 52.503 56.709 57.588 44.681
    Accounts Payable 4.598 4.421 3.391 3.975 2.529
    Accrued Expenses 39.867 30.261 22.162 31.546 25.221
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 13.341 17.821 31.156 22.067 16.931
    Total Liabilities 64.663 68.602 73.566 75.209 63.073
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 6.857 16.099 16.857 17.621 18.392
    Total Equity 348.548 375.294 333.661 300.421 270.041
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.107 0.107 0.106 0.105 0.104
    Additional Paid-In Capital 261.998 257.976 254.114 250.43 245.514
    Retained Earnings (Accumulated Deficit) 86.428 117.192 79.43 49.862 24.391
    Other Equity, Total 0.015 0.019 0.011 0.024 0.032
    Total Liabilities & Shareholders’ Equity 413.211 443.896 407.227 375.63 333.114
    Total Common Shares Outstanding 106.605 106.501 105.938 105.263 104.065
    Intangibles, Net 167.108 175.595 184.083 32.471 33.051
    Long Term Investments 12.897
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 83.079 39.482 74.983 31.8753 -34.0035
    Cash From Operating Activities 116.047 60.372 45.0349 34.6115 -25.7044
    Cash From Operating Activities 0.141 0.192 0.09207 0.05433 0.03798
    Non-Cash Items 13.063 6.36 7.04198 3.77741 3.55064
    Changes in Working Capital 13.729 5.022 -4.11092 -1.0956 4.71049
    Cash From Investing Activities 9.209 -11.021 -5.0114 37.2246 -15.526
    Capital Expenditures -0.029 -1.021 -0.0114 -0.01937 -0.09202
    Other Investing Cash Flow Items, Total 9.238 -10 -5 37.244 -15.434
    Cash From Financing Activities 1.694 -8.143 0.70193 1.11624 0.29312
    Financing Cash Flow Items -0.968 -0.153 -0.0562 0 -0.00445
    Issuance (Retirement) of Stock, Net 2.662 -7.99 0.75813 1.11624 0.29756
    Net Change in Cash 126.95 41.208 40.7254 72.9523 -40.9373
    Deferred Taxes 4.937 9.316 -32.9713
    Amortization 1.098
    Cash Taxes Paid -7.667
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 29.568 83.079 57.608 34.86 13.241
    Cash From Operating Activities 12.07 116.047 75.97 34.669 8.478
    Cash From Operating Activities 0.069 0.141 0.106 0.071 0.034
    Deferred Taxes -1.519 4.937 3.652 2.718 1.901
    Non-Cash Items 3.086 13.063 11.074 4.69 1.961
    Changes in Working Capital -25.665 13.729 3.012 -7.67 -8.659
    Cash From Investing Activities -162.367 9.209 9.209 9.341 0
    Capital Expenditures -0.074 -0.029 -0.029 -0.029 0
    Other Investing Cash Flow Items, Total -162.293 9.238 9.238 9.37 0
    Cash From Financing Activities 0.149 1.694 -0.559 -4.543 -1.551
    Issuance (Retirement) of Stock, Net 1.27 2.662 -0.539 -4.523 -1.551
    Net Change in Cash -150.148 126.95 84.62 39.467 6.927
    Financing Cash Flow Items -1.121 -0.968 -0.02 -0.02
    Cash Taxes Paid 0 -7.667 6.344 5.844 0.041
    Amortization 6.531 1.098 0.518
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    BlackRock Institutional Trust Company, N.A. Investment Advisor 13.4266 14310459 236177 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 8.8692 9453077 1910359 2023-06-30 LOW
    Deerfield Management Company, L.P. Hedge Fund 7.686 8192000 -2163099 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.4311 6854463 -54698 2023-06-30 LOW
    McEnany (Patrick James) Individual Investor 3.8649 4119285 0 2023-07-05 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.3197 2472410 97902 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8074 1926415 72193 2023-06-30 LOW
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.311 1397263 103323 2023-06-30 MED
    Renaissance Technologies LLC Hedge Fund 1.0836 1154900 64800 2023-06-30 HIGH
    Invesco Capital Management LLC Investment Advisor 1.0421 1110731 71095 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 0.9915 1056798 62240 2023-06-30 LOW
    Royce Investment Partners Investment Advisor/Hedge Fund 0.9758 1039988 424020 2023-06-30 LOW
    LSV Asset Management Investment Advisor 0.9267 987669 29869 2023-06-30 LOW
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.8914 950125 11632 2023-06-30 LOW
    Charles Schwab Investment Management, Inc. Investment Advisor 0.81 863309 -355866 2023-06-30 LOW
    Numeric Investors LLC Investment Advisor/Hedge Fund 0.7834 835008 -64815 2023-06-30 MED
    Goldman Sachs & Company, Inc. Research Firm 0.75 799363 143611 2023-06-30 MED
    American Century Investment Management, Inc. Investment Advisor/Hedge Fund 0.6997 745781 -66425 2023-06-30 LOW
    Rafferty Asset Management LLC Investment Advisor/Hedge Fund 0.6707 714875 250208 2023-06-30 MED
    Miller (Steven R) Individual Investor 0.645 687457 1 2023-07-05 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Catalyst Pharmaceuticals Company profile

    About Catalyst Pharmaceuticals Inc

    Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Catalyst Pharmaceuticals Inc revenues increased 18% to $140.8M. Net income decreased 47% to $39.5M. Revenues reflect Revenues increase of 16% to $138M. Net income was offset by Selling, general and adminis - Balancing increase of 14% to $45.2M (expense), reasear increase of 3% to $15.3M (expense), Other income, net decrease of 52% to $282K (income).

    Equity composition

    Common Stock $.001 Par, 4/11, 100M auth., 21,654,680 issd. Insiders own 22.54%. IPO 8/11/06, 3,350,000 shares @ $6 per share by First Albany Capital Inc. and Stifel, Nicolaus & Company, Incorporated. 9/08, P.O of 1.5M shares.

    Industry: Biopharmaceuticals

    355 Alhambra Circle
    Suite 801
    CORAL GABLES
    FLORIDA 33134
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    44,252.10 Price
    +2.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.68 Price
    +4.560% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading